2-(3-氧代-2-哌嗪基)乙酸乙酯 | 33422-35-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(3-氧代-2-哌嗪基)乙酸乙酯
• 中文别名: 2-(3-氧代-2-吡嗪基)乙酸乙酯；2-(3-氧-2-哌嗪基)乙酸乙酯
• 英文名称: ethyl 2-(3-oxopiperazin-2-yl)acetate
• 英文别名: ethyl 2-(3-carbonylpiperazin-2-yl)acetate；3-ethoxycarbonylmethyl-2-oxopiperazine
• CAS: 33422-35-4
• 化学式: C₈H₁₄N₂O₃
• mdl: MFCD00052897
• 分子量: 186.211
• InChiKey: HNYRNJAZRKCHSC-UHFFFAOYSA-N

物化性质

• 熔点：
  110-111°C
• 沸点：
  360.6±27.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	Ethyl 2-(3-oxo-2-piperazinyl)acetate 97% Material Safety Data Sheet
Synonym:	Ethyl 2-piperazin-3-one acetat
CAS:	33422-35-4

Section 1 - Chemical Product MSDS Name:Ethyl 2-(3-oxo-2-piperazinyl)acetate 97% Material Safety Data Sheet
Synonym:Ethyl 2-piperazin-3-one acetat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
33422-35-4	Ethyl 2-(3-oxo-2-piperazinyl)acetate	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 33422-35-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 108 - 110 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H14N2O3
Molecular Weight: 186.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 33422-35-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2-(3-oxo-2-piperazinyl)acetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 33422-35-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 33422-35-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 33422-35-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(3-氧代-2-哌嗪基)乙酸乙酯 在 吡啶 、 水 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 2-(1-(2,4-dichlorophenylsulfonyl)-3-oxopiperazin-2-yl)acetic acid
  参考文献：
  名称：

  3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation

  摘要：

  The discovery of novel and highly potent oxopiperazine based B1 receptor antagonists is described. Compared to the previously described arylsulfonylated (R)-3-amino-3-phenylpropionic acid series, the current compounds showed improved in vitro potency and metabolic stability. Compound 17, 2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-2-piperazinyl)-N-((1R)-6-(1-piperidinylmethyl)-1,2,3,4-tetrahydro-1-naphthalenyl) acetamide, showed EC(50) of 10.3 nM in a rabbit biochemical challenge model. The practical syntheses of chiral arylsulfonylated oxopiperazine acetic acids are also described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.115
• 作为产物：
  描述：

  乙二胺 、 马来酸二乙酯 以 异丙醇 为溶剂， 反应 6.0h， 以60.8%的产率得到2-(3-氧代-2-哌嗪基)乙酸乙酯
  参考文献：
  名称：

  一系列天门冬氨酸氨基甲酸酯酶抑制剂的合成和生物活性：N-取代的二乙基天冬氨酸盐和N-取代的3-氧代-1、4-哌嗪-2-乙酸酯

  摘要：

  合成了一系列的N-取代的天门冬氨酸二乙酯和N-取代的-3-氧代-1，4-哌嗪-2-乙酸酯作为天冬氨酸转氨甲酰酶的潜在抑制剂。通过将取代的烷基胺加到马来酸二乙酯中或将羟乙基氨基加合物转化成其他官能团来获得天冬氨酸。通过将乙二胺加到马来酸二乙酯中，然后环化来制备3-氧代-1，4-哌嗪-2-乙酸酯。加入1，2-二氨基-2-甲基丙烷得到相应的5，5-二甲基-3-氧代-1，4-哌嗪-2-乙酸酯。使用溴酰氯获得每个系列中的N-酰基衍生物。每个系列中的大多数化合物显示出对五种代表性微生物的抗菌活性，以及​​对天冬氨酸转氨甲酰酶的显着活性。发现其中的四种化合物对几种肿瘤细胞系具有显着的特异性。在开链天门冬氨酸或环状哌嗪中，发现两个碳原子之间的距离为N且具有反应性功能，以提供最佳的抗微生物，抗酶或肿瘤细胞特异性活性。天冬氨酸和哌嗪之间抗酶活性几乎没有差异，但是引入平面苯基取代基降低了抑制活性。

  DOI：

  10.1002/jps.2600790519

文献信息

• [EN] C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY<br/>[FR] TRITERPÉNOÏDES MODIFIÉS EN C-17 ET C-3 PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE LA MATURATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012106190A1

  公开（公告）日：2012-08-09

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已列出。具体来说，提供了具有独特抗病毒活性的C-17和C-3修饰三萜类化合物，作为HIV成熟抑制剂，如公式I、II和III所代表的化合物。这些化合物对治疗HIV和艾滋病有用。
• [EN] ETHYNYL DERIVATIVES<br/>[FR] DÉRIVÉS D'ÉTHYNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017021384A1

  公开（公告）日：2017-02-09

  The present invention relates to compounds of formula (I) wherein R1 is hydrogen, F or CI; L is a bond or lower alkylene; R2 is -(CH2)nO-lower alkyl, lower alkyl substituted by halogen, -(CH2)nC(0)0-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, =0, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by -(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or -(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

  本发明涉及以下式(I)的化合物，其中R1是氢、F或Cl；L是键或较低的烷基；R2是-(CH2)nO-较低烷基、受卤素取代的较低烷基、-(CH2)nC(0)0-较低烷基、受较低烷基或卤素取代的苯基、或是5或6-成员杂环芳基，选自吡啶基、嘧啶基、吡啉基、噻唑基、咪唑基、吡唑基或三唑基，可以选择地受较低烷基、卤素、较低烷氧基、=0、苄氧基、环烷氧基、羟基、氰基、受卤素取代的较低烷基、或者是-(CH2)nO-较低烷基取代；n为1、2或3；R3是氢、较低烷基或-(CH2)nO-较低烷基；R4是苯基、吡啶基或嘧啶基，可以选择地受F取代；Y是CF或CCl；或者是其药学上可接受的盐或酸加合盐，或者是外消旋混合物，或者是其对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗帕金森病、焦虑、呕吐、强迫症、自闭症、神经保护、癌症、抑郁症和2型糖尿病。
• [EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2017201161A1

  公开（公告）日：2017-11-23

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别是，本发明涉及不可逆地抑制KRas G12C活性的化合物，包括含有这些化合物的药物组合物及其使用方法。
• KRAS G12C INHIBITORS
  申请人：Mirati Therapeutics, Inc.

  公开号：US20190144444A1

  公开（公告）日：2019-05-16

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别地，本发明涉及不可逆抑制KRas G12C活性的化合物、包含这些化合物的药物组合物及其使用方法。
• ORGANIC SALTS AND METHOD FOR PRODUCING CHIRAL ORGANIC COMPOUNDS
  申请人：List Benjamin

  公开号：US20090030216A1

  公开（公告）日：2009-01-29

  The invention relates to a method for producing chiral organic compounds by asymmetric catalysis, using ionic catalysts comprising a chiral catalyst anion. The claimed method is suitable for reactions which are carried out over cationic intermediate stages, such as iminium ions or acyl pyridinium ions. The invention enables the production of chiral compounds with high ee values, that until now could only be obtained by means of costly purification methods.

  该发明涉及一种通过不对称催化制备手性有机化合物的方法，使用包括手性催化剂阴离子的离子催化剂。所述方法适用于在阳离子中间体阶段进行的反应，例如亚胺离子或酰基吡啶离子。该发明实现了具有高ee值的手性化合物的生产，直到现在只能通过昂贵的纯化方法获得。